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Cancer is not an uncommon diagnosis in children. The incidence 
of childhood cancer (generally referring to children up to the age of 
15) is 110 - 130 per million children per annum.1 It is estimated that 
the cumulative risk of a child being diagnosed with cancer is slightly 
higher in boys (1:444) compared with girls (1:594).2 In South Africa 
accurate figures for childhood cancer are not available. The reported 
incidence is around 70 - 80 per million. However, it is estimated 
that one in 600 children will suffer from cancer before they turn 16. 
Many of these cancers are diagnosed late or may not be diagnosed at 
all.3
The prognosis for patients with cancer diagnosed under the age of 
15 has improved dramatically over the past 30 years. More than 80% 
survive longer than 5 years, and more than 70% will be long-term 
survivors. Information from cancer statistics during the 1970s to 
1980s indicate that in the USA, the cure rate of all childhood cancers 
combined was between 70% and 90% (Table 1).4 The estimated 
5-year survival of children of both sexes improved form 50.4% in 
1973 to 79.2% in 1990.5  
Neuroblastomas and Wilms’ tumours occur most commonly in 
infants less than 5 years old, while Hodgkin’s lymphoma and bone 
tumours usually present in the teenage years and early adult life. 
Leukaemia may occur at all ages.  
Older children and young adults have historically not been 
studied to the same extent as young children with regard to 
cancer incidence. The age range for adolescence for the purpose 
of scientific reporting has been set at 15 - 19 years.6 More recently 
the concept of ‘young adult oncology’ has referred to a larger group 
of young people between the ages of 15 and 29 years.7 This group 
is at an important developmental phase, particularly with regard 
to establishment of normal hormonal and sexual function. The 
spectrum of cancers affecting this group differs from that in younger 
children and adults and is summarised in Table 2. 
Tumours of the male and female genital tracts become more 
common in the young adult group. Testicular cancer is the 
commonest form of solid malignancy among young adult males, 
and the frequency increases with age from 15 to 29 years.8 Cure 
rates for men with seminomas exceed 90%, but non-seminomatous 
tumours have a poorer outcome. In young women 18% of 
total malignancies are of gynaecological origin.9 Carcinoma of 
the cervix becomes more frequent, while germ cell tumours, 
particularly dysgerminomas, represent the most common ovarian 
malignancies. 
It is estimated that 1 in 570 adults are cancer survivors and that this 
may increase to 1 in every 250.5 The increased cure rate means that 
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Table 1. Incidence and survival figures for common childhood malignancies69
Incidence/100 000/year Cure rate (%)
ALL/non-Hodgkin’s lymphoma 5.0 - 6.0 78 - 80
Hodgkin’s lymphoma 0.4 >90
Brain tumours 4.0 Depends on type
Wilms’ tumours 0.9 80
ALL = acute lymphoblastic leukaemia.
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many more patients with a history of cancer will reach adulthood 
and want to have children. The reproductive system is an important 
site for late side-effects of cancer treatment, and normal pubertal 
development depends on an undamaged hypothalamic-pituitary-
gonadal axis. Practitioners should be aware of the potential harm 
to the endocrine and reproductive systems after life-saving but 
potentially toxic chemo- and/or radiotherapy. Fertility can also be 
compromised by chemotherapy, radiotherapy of the hypothalamic-
pituitary-gonadal axis or surgery. Chemotherapy and radiotherapy 
may also be used in patients with non-malignant auto-immune 
diseases such as systemic lupus erythematosus and rheumatoid 
arthritis, as well as certain haematological diseases.10
The effects of chemotherapy on the ovary
In females the production of sex hormones requires the presence 
of germ cells. Young women will experience endocrine function 
loss more often than men after chemo- and radiotherapy in 
childhood and adolescence. Unlike men, women have a fixed 
number of germ cells that gradually diminish with age. At puberty, 
between 200 000 and 400 000 follicles are present which may 
eventually mature, but only 400 - 500 mature oocytes are produced 
in a normal reproductive lifespan.11 At the age of menopause only 
a few hundred follicles are left.12 Anti-cancer therapy may increase 
the rate of follicular loss and therefore lead to premature ovarian 
failure. Premature menopause is one of the common toxic side-
effects of cancer treatment.13 Chemotherapy may affect the ovary 
to cause amenorrhoea in 40 - 68% of cases, depending on various 
factors.14 
Mechanisms of damage to ovarian 
function 
The pharmacological action of chemotherapy is mainly aimed 
at disrupting the process of DNA synthesis and cell replication. 
In general the alkylating agents interact with DNA, preventing 
replication and/or transcription. Anti-tumour antibiotics such 
as actinomycin D work on the same principle. Other agents may 
damage the structure of DNA directly, while adriamycin acts by 
damaging the plasma membrane. The plant-based chemotherapy 
agents such as the taxanes disrupt the function of tubulin, which is 
critical in the normal mitotic process.
Specific chemotherapy agents, particularly the alkylating ones such 
as cyclophosphamide and chlorambucil, may cause permanent 
DNA damage in ovarian follicles. Other chemotherapy agents are 
less harmful, and include 5-fluorouracil, methotrexate, etoposide 
and adriamycin.15 There are various mechanisms of damage to the 
ovaries. The damage may be directly to the primordial follicles with 
death of follicular cells. Human and animal studies have shown 
that chemotherapy can damage ovarian pre-granulosa cells,16 with 
increased apoptosis during oocyte and follicle loss.17 Vascular 
effects associated with antineoplastic agents have been reported, 
and recognised mechanisms for such toxicity include drug-
induced endovascular damage.18 In a descriptive study Meirow and 
co-workers studied the histological features of ovarian tissue from 
17 women exposed to chemotherapy and compared them with 18 
patients who were not exposed.19 The pathologists were blinded 
for patient characteristics. They found injury to blood vessels and 
focal fibrosis of the ovarian cortex in ovaries of patients previously 
exposed to chemotherapy. Blood supply for the ovarian cortex is by 
an end-artery system and the cortex is a fairly poorly oxygenised 
tissue. After chemotherapy there is prominent thickening and 
narrowing of the vessels, and neo-vascularisation with abnormal 
blood vessels to the ovarian cortex is seen on microscopy. There is 
also cortical fibrosis. Direct damage to the follicles can also be seen 
after chemotherapy. 
Mature follicles are more vulnerable to chemotherapy damage.20 
Certain endocrine mechanisms may play a role in the damage to 
larger follicles. Anti-Müllerian hormone (AMH) is mainly secreted 
by growing follicles and AMH levels drop significantly during 
therapy.21 A drop in AMH may cause raised recruitment and make 
more follicles vulnerable to damage due to chemotherpy. 
AMH may be used as a marker of ovarian reserve. Serum AMH 
levels can be measured to assess sub-clinical ovarian damage in 
patients treated with chemotherapy.22 A possible mechanism to 
protect ovarian function may be to administer anti-Müllerian 
hormone during treatment with chemotherapy to reduce 
recruitment of follicles.
Age at treatment
One of the most important clinical factors that influence the risk for 
permanent ovarian damage is age at treatment. The risk for ovarian 
failure increases with age (Table 3).23-26 This is because the number of 
primordial follicles is far higher at a younger age. 
Amenorrhoea due to chemotherapy is more common in women 
who were over the age of 30 years at the time of treatment (50 
Table 2. The relative frequencies (%) of cancers in adolescents 
and young adults aged 15 - 29 years69
Age (yrs)
15 - 19 20 - 24 25 - 29
Lymphoma 26 22 16
Leukaemia 12 7 4
Central nervous system 10 7 5
Endocrine system 9 12 11
Skin 8 14 18
Male genital 8 13 11
Female genital 8 8 12
Bone and joint 8 3 1
Soft tissue 5 3 2
Digestive system 2 3 5
Oropharynx 2 3 2
Respiratory system 2 2 2
Urinary system 2 2 2
Breast 0 2 8
Other 2 2 1
Table 3. The effect of age on the rate of premature ovarian 
failure after cyclophosphamide chemotherapy8
Age (yrs) Premature ovarian failure (%)
<20 13
20 - 30 50
>30 100
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- 89%) compared with younger women, where normal menses 
was preserved in 48 - 100% of cases.27-29 Chemotherapy-related 
amenorrhoea may be transient. However, if the condition is present 
for more than 1 year after treatment, less than 11% of women over 
the age of 40 years and only 12 - 15% of women younger than 40 will 
experience a return to menses.30 
Treatment for young people with cancer 
The most common forms of malignancies affecting young people 
and the treatment for these malignancies are summarised in Table 4. 
It is clear that multi-agent chemotherapy regimens and radiation may 
contribute to reproductive failure. It is often difficult to determine the 
individual effect of specific therapies on fertility outcome.
Haematological malignancies
There are a significant number of reports in the literature about the 
effects of chemotherapy on fertility and hormonal function after 
treatment for haematological malignancies in younger women. 
Treatment for Hodgkin’s lymphoma with MVPP (mechlorethamine, 
vinblastine, procarbazine and prednisolone), MOPP (mechloretha-
mine, vincristine, procarbazine and prednisolone) or ChIVPP 
(chlorambucil, vinblastine, procarbazine and prednisolone) 
resulted in permanent ovarian failure in 19 - 63% of cases.23-27 
Treatment for acute lymphoblastic leukaemia (ALL), however, had 
less long-term risk for permanent amenorrhoea.31,32 Conditioning 
with chemotherapy before bone marrow transplantation is usually 
associated with transient amenorrhoea. Cyclophosphamide doses 
of 200 mg/kg caused amenorrhoea in all women on treatment, 
but all recovered normal ovarian function after bone marrow 
transplantation.33 Doses higher than 200 mg/kg may cause 
premature ovarian failure.34 Multi-agent combination chemotherapy 
regimens may have synergistic toxicity, and the specific contribution 
of each agent is often difficult to determine.
Breast cancer
In the USA breast cancer is the most common cancer in women 
of reproductive age (<40 years of age), and approximately 13% of 
all breast cancer diagnoses are made in women younger than 45.35 
Alkylating agents (e.g. cyclophosphamide) are often included in the 
treatment plans for breast cancer. The higher the cumulative dose 
of cyclophosphamide, the higher the risk of premature menopause. 
In cases treated with CMF (cyclophosphamide, methotrexate and 
5-flurouracil) the incidence of amenorrhoea was 61% in patients 
younger than 40 years and 95% in patients older than 40 years.26 A 
slightly higher incidence of amenorrhoea was found with a regimen 
containing FEC (fluorouracil, epirubicine and cyclophosphamide) 
compared with CMF (51% v. 42.6%).36 Anthracycline-based 
regimens had a lower incidence of amenorrhoea.15 There is very 
little evidence with regard to taxanes and the risk of subsequent 
amenorrhoea, but there does not appear to be an increased overall 
risk when it is added to chemotherapy regimens.37 
Pregnancy after chemotherapy
Maltaris et al. summarised the obstetric outcome in patients 
with previous epithelial ovarian carcinoma after receiving 
fertility-preserving treatment.37 Not all of the patients received 
chemotherapy. A total of eight studies were included in the review, 
and 113 pregnancies were described out of the total of 282 patients. 
The number of term deliveries was 87. In this group the number of 
reported relapses of ovarian carcinoma was 33 and that of disease-
related deaths 16. 
In a study reported by Newlands et al., cyclophosphamide therapy 
for choriocarcinoma was associated with a reduction in the fertility 
rate when compared with treatment with methotrexate only;38 79% 
of the total number of patients desiring pregnancy had at least one 
live birth after cyclophosphamide, compared with 86% in those who 
received methotrexate only.
Radiotherapy damage to hormone 
production and fertility in women
The extent of radiotherapy damage to ovarian function and 
reproduction is determined by the total dose of radiation, the 
fractionation schedule, and the age of the patient at the time of 
treatment.13,39 The human oocyte is exquisitely sensitive to the 
damaging effects of radiation, and the estimated median lethal 
dose (LD50) is less than 4 Gy.13 A descriptive study by Wallace et 
al. found that 37 of 38 females developed ovarian failure after 
whole-abdominal irradiation in childhood of 20 - 30 Gy; 71% had 
primary amenorrhoea, i.e. never had normal pubertal development, 
and premature menopause occurred in the rest at a median age of 
23.5 years.39 Total-body irradiation (TBI) is sometimes used alone 
or in combination with cyclophosphamide as conditioning for 
bone marrow transplantation. This treatment is often associated 
with infertility, and only a small number of patients (9 out of 
144) had normal ovarian function after TBI at a dose of 9 - 16 
Gy combined with cyclophosphamide 120 mg/kg before bone 
marrow transplantation. The effect of age at treatment was also 
demonstrated in this study, with a greater probability of recovery of 
ovarian function observed in younger girls.33  
The uterus may be damaged by radiotherapy, and reduced uterine 
volume and decreased elasticity of the myometrium can be found 
in girls who received pelvic or abdominal irradiation or TBI 
Table 4. Treatment of childhood cancers14
Chemotherapy Cranial radiation therapy Gonadal radiation therapy
Acute lymphoblastic leukaemia + ± ±
Non-Hodgkin’s lymphoma + ± ±
Hodgkin’s lymphoma + - ±
Brain tumours ± ± ±
Wilms’ tumour + - ±
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before puberty.40,41 Even though successful pregnancies following 
radiotherapy have been reported, there is an increased incidence 
of miscarriage, intra-uterine growth restriction and premature 
delivery.31 It is difficult to measure uterine damage after exposure to 
radiotherapy, but endometrial sampling may help in the assessment 
of endometrial function. Exact prediction of eventual reproductive 
outcome, however, is very difficult.
It is clear from Table 5 that the risk of premature ovarian failure is 
higher if the patient receives treatment at an older age. 
Ovarian trans-position outside the field of radiotherapy may 
reduce the dose to the ovary. Howell and Shalet described how 
lateral transposition of the ovaries to the para-colic gutters may 
reduce the radiotherapy dose by up to 95%.42 This may protect the 
sensitive follicles from direct dose-related damage. Other reports, 
however, were less optimistic and found that ovarian transposition 
may compromise blood supply, and there was mixed success with 
this technique due to scattered radiation and vascular compromise.43 
Ovarian transposition may have a place in cases where the pelvic 
dose of radiotherapy is not high enough to be damaging to the other 
organs in the reproductive tract. 
Cranial irradiation may cause hypo-pituitarism in doses over 30 
Gy.44,45 Up to 60% of patients experienced a gonadotropin deficiency 
4 years after treatment with cranial irradiation.45 Effects on other 
pituitary hormones such as growth hormones have also been 
reported.46 In a report by Nygaard et al., a cranial radiation dose of 
between 18 and 24 Gy was identified as a possible risk factor for a 
significantly lower first birth rate compared with women without 
any radiation.47 The presence of a regular menstrual cycle may not 
be an adequate indication of hypothalamic-pituitary function, 
and sub-fertile women who received cranial radiation need careful 
hormonal assessment.
Chemotherapy and testicular function
In men endocrine and exocrine functions of the gonads are 
separated. The average age of spermarche is 13.4 years. The 
alkylating agents are gonadotoxic, with procarbazine particularly 
harmful. This is a very useful drug used in the treatment of 
Hodgkin’s lymphoma, where repeated courses of alkylating 
agents are often needed. The Sertoli and germ cells are more 
chemosensitive than the Leydig cells; a patient with normal 
testosterone production may therefore have azoospermia.48 
Azoospermia is likely if the volumes of the post-pubertal testes are 
less than 10 ml each as measured by the Prader orchidometer. 
It is clear that in multi-agent chemotherapy regimens there may be 
synergistic toxicity of individual agents, and it is often very difficult 
to determine the specific contribution of each agent. Certain agents 
have been identified as particularly gonadotoxic to the testes, 
including the alkalating agents procarbazine, cisplatinum and 
vinblastine.49-56 Cyclophosphamide may cause azoospermia in up 
to 13% and oligozoospermia in 30% of patients treated with a total 
dose of 560 - 840 mg/kg.53 Ifosfamide is sometimes used for the 
treatment of sarcomas, and a dose of between 84 and 126 mg/m2 was 
associated with impaired spermatogenesis.57 Newer combinations 
such as the ABVD combination (adriamycin, bleomycin, vinblastine 
and decarbazine) have been shown to be less gonadotoxic, with 
full testicular recovery after 18 months of treatment in nearly all 
patients.55 The testicular seminiferous epithelium that is responsible 
for spermatogenesis is more sensitive to the effects of chemotherapy; 
however, the Leydig cells are more resistant to damage and in 
certain cases, although secondary sexual characteristics may develop 
normally, there may be severe impairment of sperm production.48,58 
In higher cumulative doses Leydig cells may also be damaged,59 but 
this rarely occurs in clinical practice. 
Radiotherapy and testicular function
Radiotherapy may damage the hypothalamic-pituitary axis if the 
dose is more than 30 Gy to the cranial region. Radiotherapy may 
also damage the testes; the damage may be reversible if the dose is 
between 20 and 200 cGy, but irreversible azoospermia will develop 
over 400 cGy. Low production of testosterone will only occur when 
the dose goes above 1 500 cGy.
Pubertal development is usually normal after treatment with TBI 
in preparation for bone marrow transplantation.60 It was found 
that these boys had slightly higher levels of follicle-stimulating 
hormone and that mean testicular volume was lower than normal 
at an average of 10.5 ml. Luteinising hormone (LH) was elevated, 
which may indicate subtle hormonal dysfunction of the Leydig 
cells.60 Other reported studies found no change in LH levels after 
preparation for bone marrow transplantation.61,62
Conclusion
‘First do no harm’ is an important precept of Hippocrates (around 
460 - 377 BC). Non-maleficence, which is the ethical principle that 
flows from this, is fundamental to medical ethics. Beneficence refers 
to actions that promote the wellbeing of others. In the management 
of serious disease such as cancer there is often a conflict between 
these two moral imperatives. The obligation not to harm others is 
usually more stringent than the obligation to help others. In an 
effort to cure cancer (an act of beneficence) the treatment itself 
may at the same time also cause significant harm. Many treatments 
have serious, harmful late effects including an effect on future 
fertility and hormone production. Every young patient deserves 
safe and effective oncological treatment but with the least long-
Table 5. The effect of radiation on ovarian function69
Dose (Gy) Ovary
0.6 No deleterious effect
1.5 No effect in <40 yrs
Some risk of POF in >40 yrs
5 60%  sterile <40 yrs
100% sterile >40 yrs
8 70%  sterile <40 yrs
100% sterile >40 yrs
>8 100% sterile
POF = premature ovarian failure.
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term negative effects. A multi-disciplinary team approach involving 
oncologist, surgeon and counsellor should include a reproductive 
health specialist if fertility may be compromised by cancer therapy. 
Clinicians should consider the long-term side-effects of treatment 
before mapping out a treatment plan, and use fertility-sparing 
techniques where appropriate.
It is important to consider collecting a semen sample before the 
initiation of chemotherapy.58 Cryopreservation of sperm is a well-
known technique and has excellent outcomes. If pre-pubertal boys 
cannot produce a sample through masturbation, testicular biopsies 
are a viable alternative.
In certain clinical situations the ovaries of a young woman will 
be exposed to high doses of toxic cancer therapy. If surgical 
transposition will be of no benefit due to systemic chemotherapy, 
an option may be to remove ovarian tissue for the period of therapy. 
Preservation of ovarian tissue before cancer treatment and later 
transplantation of the tissue (when toxic treatment is finished) may 
restore hormonal function and sometimes even fertility. The self-
evident candidates for ovarian tissue or oocyte cryopreservation 
are young women and girls with haematological cancer who need 
aggressive chemotherapy regimens. 
There are indications that, with improving technical ability, slow-
freezing of oocytes is becoming more efficient with increases in 
survival rates of individual oocytes, better fertilisation rates and 
ultimately an improvement in pregnancy rates.63 More recently, 
vitrification (ultra-rapid cooling technique) of human oocytes has 
been described, and the success rate after vitrification seems to be 
improving.64 
Despite the experimental nature of ovarian tissue cryopreservation, 
ovarian tissue harvesting and banking has been offered to many 
patients in clinical practice over the past two decades.65-67 Case 
reports of successful pregnancy from cryopreserved ovarian tissue 
give hope that this technique may become part of clinical practice.68
Cryotherapy techniques offer real hope to boys and girls who need 
gonadotoxic therapy, and ovarian tissue, testicular tissue, sperm and 
ova may be harvested and stored before treatment is started. 
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